The Role of xMAP® Multiplex Assays in the Development of HPV Vaccines

HPV vaccines must prevent multiple HPV types in order to be effective and during vaccine development, a large number of HPV proteins may need to be evaluated as prospective vaccine components. Multiplex assays are therefore necessary to quantitatively measure the large number of antibodies generated and evaluated. HPV typing can be done very quickly using multiplexed DNA hybridization assays. Based on Luminex® xMAP® Technology, the reproducible, fast, sensitive, and highly multiplexed assays for these DNA sequences and antibodies are optimal solutions for monitoring HPV types and vaccine immune response.